Dr. Christian Schneider is a Managing Partner of Vesalius Biocapital and has been a venture capital executive for the past 17 years. As a life science expert, he has extensive hands-on work and investment experience in the areas of diagnostics, medtech, and therapeutics. As shareholder and board member he actively supports and advices start-up companies.
Starting as an R&D scientist at Boehringer Mannheim / Roche (Tutzing/Penzberg, Germany, 1992-1995), he developed automated tests for the early detection of cancer. At Centocor (Malvern, Pennsylvania, USA, 1995-2000, sold to Johnson&Johnson for USD 5B in 1999), he led diagnostic product development in transatlantic collaborations. Later, as a business developer and external research manager in Centocor’s / Johnson&Johnson’s biological therapeutics business, he negotiated, financed, and managed international early-stage product development projects.
As a Managing Partner of venture capital firm PolyTechnos (Germany 2001-2008), he was directly responsible for the investments in and IPOs of OncoMethylome Sciences (Euronext, 2006), Devgen (Euronext, 2005) and Jerini (Frankfurt, 2005) and served as an independent director on the boards of Hepa Wash and MagnaMedics. In 2008, he joined the pan-European life science venture capital firm Vesalius Biocapital as a Managing Partner with responsibility for the investments and exits of Skyline (write-off) and Activaero (EUR 130m trade sale to Vectura, 2014). Across three Vesalius fund generations, he serves on the boards of portfolio companies Ventaleon, Omeicos, Humedics and Softhale.
Dr. Schneider holds a doctorate degree in veterinary medicine (1992) and a PhD in immunology (1995), both from the University of Munich, Germany, and an MBA in healthcare administration from Penn State University, Pennsylvania (1999).